Receptor-Associated Protein (RAP), AmpTide(TM), may proved useful in treatment of cancers, including mesothelioma
Monday, April 16th, 2007.
Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP.OB), today announced its quarterly financial results. As a result of several research programs and operations overhead, expenses are anticipated to increase over the next twelve months.One of the programs involves research into a novel drug used to treat mesothelioma called AmpTide(TM).
AmpTide(TM) for Lung Cancer (Mesothelioma)
Raptor Pharmaceuticals has engineered a Receptor-Associated Protein (RAP) peptide, known as AmpTide(TM), to selectively bind a critical part of matriptase, a protein that is over- produced on lung cancer (mesothelioma) cells. Matriptase has been shown to enable tumor cells to aggressively invade surrounding tissues and thereby support tumor growth. In the fourth calendar quarter of 2007, Raptor Pharmaceuticals plans to test whether AmpTide(TM) interferes with the tumor-promoting activity of matriptase. Such interference may be useful in the treatment of a variety of cancers, including mesothelioma, which are known to over-produce matriptase.
About Raptor
Raptor Pharmaceuticals Corp.’s sole business is its 100% ownership of Raptor Pharmaceutical Inc., an early stage biotechnology research and development company which bioengineers novel drugs and drug-targeting platforms derived from the human receptor-associated protein (RAP) and related proteins.
« Mesothelioma News Main Page.
Most Recent in
Drug Companies
- 08/03/12 - MolMed: NGR-hTNF: increased recruitment rate – with completion foreseen by the end of the year – in the Phase III mesothelioma trial, and new European patent granted
- 07/18/12 - Bayer HealthCare receives Orphan Drug Designation for its Anti-Cancer Agent in the U.S. for the Treatment of Mesothelioma
- 10/12/10 - Raltitrexed (Tomudex®) in Combination With Cisplatin in the Treatment of MPM Improves Overall Survival Compared to Treatment With Cisplatin Alone
- 04/20/10 - MolMed starts Phase III trial of NGR-hTNF in mesothelioma
- 04/13/10 - microRNAs Shown To Have Powerful Potential as Diagnostic and Prognostic Markers In A Variety Of Cancer Indications
Most Recent in
Novel Treatments & Drugs
- 08/30/12 - Asbestos Update: Nanofibres, Drugstore Cowboy, Non-lung Asbestos Cancers
- 08/03/12 - MolMed: NGR-hTNF: increased recruitment rate – with completion foreseen by the end of the year – in the Phase III mesothelioma trial, and new European patent granted
- 07/18/12 - Bayer HealthCare receives Orphan Drug Designation for its Anti-Cancer Agent in the U.S. for the Treatment of Mesothelioma
- 10/12/10 - Raltitrexed (Tomudex®) in Combination With Cisplatin in the Treatment of MPM Improves Overall Survival Compared to Treatment With Cisplatin Alone
- 04/20/10 - MolMed starts Phase III trial of NGR-hTNF in mesothelioma
Most Recent in
Raptor Pharmaceuticals Corporation
You can follow any responses to this entry through the RSS 2.0 feed.
You can leave a response, or trackback from your own site.
